The FDA on October 2, 2020 approved the combination of OPDIVO® (Nivolumab) plus YERVOY® (Ipilimumab) as first-line treatment for adult patients with unresectable Malignant Pleural Mesothelioma. Both OPDIVO® and YERVOY® are products of Bristol-Myers Squibb Co.
Bottom Ad
Advertisement
Subscribe
